

10/586914 586914 - GAU: 1781
IAP11 Rec'd PCT/PTO 25 JUL 2006

Docket No.: 12810-00316-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Andreas Habich et al.

Application No.: National Phase of
PCT/EP2005/000827

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: STABILIZED PHOSPHATASE
FORMULATIONS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

Application No.: National Phase of PCT/EP2005/000827

Docket No.: 12810-00316-US

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 12810-00316-US.

Respectfully submitted,

By 

Hui-Ju Wu

Registration No.: 57,209
CONNOLLY BOVE LODGE & HUTZ LLP
1007 North Orange Street
P.O. Box 2207
Wilmington, Delaware 19899
(302) 658-9141
(302) 658-5614 (Fax)
Agent for Applicants

476321

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Andreas Habich
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	12810-00316-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,846,798	12-08-1998	Paatz et al.	
	AB*	US-6,475,546	11-05-2002	Harz et al.	
	AC*	US-6,810,519	08-26-2003	Henriksen et al.	
	AD*	US-2002/0034798	03-21-2002	Barendse et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² , Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO-93/16175	08-19-1993	Gist-Brocades N.V.	
	BB	WO-95/06709	03-09-1995	Cognis Gesellschaft für Bio- Und Umwelttechnologie MBH	See US 5,846,798
	BC	WO-97/16076	05-09-1997	Novo Nordisk A/S	
	BD	WO-98/28408	07-02-1998	Novo Nordisk A/S	
	BE	WO-98/54980	12-10-1998	Gist-Brocades N.V.	
	BF	WO-98/55599	12-10-1998	Gist-Brocades B.V.	
	BG	WO-00/36927	06-29-2000	BASF Aktiengesellschaft	See US 6,475,546
	BH	WO-00/47060	08-17-2000	DSM N.V.	
	BI	WO-03/059086	07-24-2003	DSM N.V.	
	BJ	WO-03/059087	07-24-2003	DSM N.V.	
	BK	WO-03/040398	05-15-2003	Battelle Memorial Institute	
	BL	DE-1958104	05-19-1971	Knapsack AG	See GB 1 288 997
	BM	DE-2137042	02-10-1972	Novo Therapeutisk Laboratorium A/S	See GB 1 362 365
	BN	DE-2137043	02-03-1972	Novo Therapeutisk Laboratorium A/S	See GB 1 361 387
	BO	EP-0 257 996	03-02-1988	Cultor Ltd.	
	BP	EP-0 716 685	06-19-1996	Henkel KGaA	See US 5,846,798
	BQ	EP-0 758 018	02-17-1997	Gist-Brocades B.V.	
	BR	EP-0 862 623	09-09-1998	Genencor International, Inc.	
	BS	EP-0 897 985	02-24-1999	DSM IP Assets B.V.	
	BT	EP-0 969 089	01-05-2000	F. Hoffmann-La Roche AG	
	BU	EP-1 069 832	01-24-2001	BASF AG	
	BV	GB-1 288 997	09-13-1972	Knapsack AG	
	BW	GB-1 362 365	08-07-1974	Novo Therapeutisk Laboratorium A/S	
	BX	GB-1 361 387	07-24-1974	Novo Therapeutisk Laboratorium A/S	
	BY	GB-2 167 758	06-04-1986	Showa Denko Kabushiki Kaisha	

Examiner Signature	/Philip Dubois/	Date Considered	07/30/2010
--------------------	-----------------	-----------------	------------

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Andreas Habich
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	12810-00316-US

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.980(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Marrs, W.M., "Rheology as an Indicator of Functionality", The World of Ingredients, 1996, pp. 38-40.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Philip Dubois/	Date Considered	07/30/2010
--------------------	-----------------	-----------------	------------

477723

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./